Captisolais Ligand Pharmaceuticalssolvent Freeall Aqueous Processed Modified Cyclodextrin That Helps You Get Your Product To Market And To Thepatients You Servecaptisol Optimized Products Havetreated Over 1 Million Patients In Morethan 120 Countries Captisolais A Polyanionic Beta Cyclodextrin Derivativewith A Sodium Sulfonatesalt Separated From Thelipophilic Cavity By A Butyl Ether Spacer Groupor Sulfobutylethersbecaptisolais Not A Singlechemical Speciesbut Comprised Of A Multitudeof Polymeric Structures Of Varying Degrees Of Substitution And Positional Regional Isomers Dictated And Controlled To A Uniform Pattern By A Patented Manufacturing Process Consistently Practiced And Improved To Control Impurities Theselection Of Captisolaand Its Desirablesafety Profileand Drug Solubilization Properties Was Based Upon Extensiveevaluations Of Themonotetra And Hepta Substituted Dominated Compositionscaptisolais Thetradenamefor Ligand S Modified Beta Cyclodextrin Technology Several Hundred Of Preclinical And Clinical Studies Havebeen Performed And Indicatethat Captisolais Safewhen Administered Parenterally Or Orally And Does Not Exhibit Thenephrotoxicity Associated With Beta Cyclodextrinrelativeto Beta Cyclodextrincaptisolaprovides Higher Interaction Characteristics And Superior Water Solubility In Excess Of 100 Grams 100 Ml Ae A 50 Fold Improvement
